Global Lateral Flow Assays Market Report 2022: Increasing Prevalence of Infectious Disease Driving Sector – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Lateral Flow Assays Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global lateral flow assays market is growing at a considerable CAGR of around 8.8% during the forecast period. The lateral flow devices are used to confirm the presence or absence of a target disease without the … [Read more…]

North America Respiratory Care Devices Market Report 2022: A $12.13 Billion Market by 2028 – Paradigm Shift Towards Value-Based Technology Solutions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Respiratory Care Devices Market Forecast to 2028 – COVID-19 Impact and Regional Analysis By Product, Indication and End User” report has been added to ResearchAndMarkets.com’s offering. The North America respiratory care devices market is expected to grow from US$ 7,319.58 million in 2022 to US$ 12,139.81 million by 2028; it is … [Read more…]

Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative

— Novel Program Supports Student Education and Future Careers in Patient Advocacy — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the College of Science. The gift will help advance Notre Dame’s Interdisciplinary Minor in Science and … [Read more…]

Endocrine Therapy Before Surgery Results in Different Outcomes in Black vs. White Women With Breast Cancer, City of Hope-Led Study Finds

The results will be presented at the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Sept. 16 to 19, and included in its press program. LOS ANGELES–(BUSINESS WIRE)–A study led by City of Hope, one of the largest cancer research and treatment organizations in the … [Read more…]

AdaptHealth Capital Markets Day to Highlight Progress Executing Strategy to Transform Healthcare by Keeping Patients Healthy at Home

Company Introduces New Long-Term Financial Goals PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will host and webcast its 2022 Capital Markets Day beginning at 9:00 a.m. ET today. During the event, Chief Executive Officer … [Read more…]

United States Behavioral Health EHR Market Trends/Analysis Report 2022: A $459 Million market by 2030 – Government Initiatives to Promote EHR Adoption – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “U.S. Behavioral Health EHR Market Size, Share & Trends Analysis Report by End Use (State-owned, Private), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. behavioral health EHR market size is expected to reach USD 459.1 million by 2030. It is expected to expand at a CAGR of 11.07% … [Read more…]

Insights on the CRISPR Global Market to 2028 – Rising Age-related Disorders are Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global CRISPR Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global CRISPR market is anticipated to grow at a substantial CAGR of 36.8 % during the forecast period. Companies Mentioned Addgene AstraZeneca PLC Bio-Rad Laboratories, Inc. Caribou Bioscience Inc. Cellectics SA Crispr Therapeutics AG Editas Medicine, Inc. Genscript Biotech Corp. Horizon … [Read more…]

Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th … [Read more…]

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to Prior Therapies1 − Positive Opinion Based on Phase 3 SOLSTICE Study Demonstrating Maribavir Was Statistically Superior to Conventional Therapies at Study Week 8, … [Read more…]

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a … [Read more…]